INSYS Therapeutics Inc. (NASDAQ:INSY) and Ardelyx Inc. (NASDAQ:ARDX) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.
Earnings and Valuation
Table 1 demonstrates INSYS Therapeutics Inc. and Ardelyx Inc.’s top-line revenue, earnings per share and valuation.
Table 2 shows the return on equity, net margins and return on assets of the two firms.
A 2.56 beta means INSYS Therapeutics Inc.’s volatility is 156.00% more than Standard and Poor’s 500’s volatility. Competitively, Ardelyx Inc. is 87.00% more volatile than Standard and Poor’s 500, because of the 1.87 beta.
0.7 and 0.6 are the respective Current Ratio and a Quick Ratio of INSYS Therapeutics Inc. Its rival Ardelyx Inc.’s Current and Quick Ratios are 12.8 and 12.8 respectively. Ardelyx Inc. has a better